In topline interim phase 1b findings, a single 720-mg subcutaneous dose of zumilokibart (APG777), Apogee Therapeutics' long-acting anti-interleukin-13 (IL-13) monoclonal antibody, produced rapid and sustained suppression of fractional exhaled nitric oxide (FeNO) in patients with mild to moderate asthma, according to Mario Castro, MD, MPH, professor of medicine and chief of the Division of Pulmonary, Critical Care and Sleep Medicine at the University of Kansas School of Medicine.
Mario Castro
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Mario
Contact Mario, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack